Answer
The estimated terminal half-life of intravenous Lunsumio (mosunetuzumab) at steady state is 16.1 days, based on population pharmacokinetic model estimates.
Sources for this answer
- Lunsumio 1 mg and 30 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 11Document updated
Sources checked